Buscar
Mostrando ítems 1-10 de 18
Generating genotype-specific aminoglycoside combinations with ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
(American Society for Microbiology, 2021)
Antibiotic combinations, including ceftazidime/avibactam (CAZ/AVI), are frequently employed to combat KPC-producing Klebsiella pneumoniae (KPC-Kp), though such combinations have not been rationally optimized. Clinical ...
Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru
(Oxford University Press, 2022)
Objectives: The objective of this study was to analyse the cost-effectiveness (C-E) of ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for pneumonia and bacteraemia caused by carbapenem-resistant ...
Nicho terapéutico de ceftazidima-avibactam frente a la multidrogo-resistencia en bacterias gram-negativas en Colombia
(MedicinaUniversidad El BosqueFacultad de Medicina, 2020)
La resistencia antibiótica es un gran problema de salud pública a
nivel mundial, debido a que aumenta la morbimortalidad por un
gran número de patologías, es el responsable de 700.000
muertes por año, y que se estima ...
Estado del perfil de susceptibilidad in vitro de Enterobacterales frente a Ceftazidime/Avibactam
(Pontificia Universidad Javeriana, 2020)
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
(2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through ...
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
(2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through ...
Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?
(American Society for Microbiology, 2017-04)
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant ...
Estado del perfil de susceptibilidad in vitro de Enterobacterales frente a Ceftazidime/Avibactam
El creciente aumento en la resistencia bacteriana muchas veces asociado a mal uso o uso indiscriminado de los antibióticos, ha ocasionado que en los últimos años se presente un aumento en dicha resistencia lo que conlleva ...
Defining substrate specificity in the ctx-m family: The role of asp240 in ceftazidime hydrolysis
(American Society for Microbiology, 2018-06)
The natural diversification of CTX-M -lactamases led to the emergence of Asp240Gly variants in the clinic that confer reduced susceptibility to ceftazidime (CAZ). In this study, we compared the impact of this substitution ...